Tag Archives: PReP

CROI 2014: PrEP pilots to launch in resource-limited settings

By on .

BOSTON, MASS – Dr. Nelly Mugo from the Kenya Medical Research Institute in Nairobi was able to summarize the use of antiretroviral drugs to prevent HIV acquisition — pre-exposure prophylaxis, or PrEP — in resource limited settings quickly this week. That is because, after a series of clinical trials demonstrating the effectiveness of that prevention […]

AVAC: HIV vaccine, microbicides, PrEP trial results say reality must guide research

By on .

For all the graphics illustrating results of HIV prevention trials in recent years, the Venn diagram on the cover of Research & Reality, the report released by AVAC today, may be the one that depicts the sum of their findings. Which is really saying something, when one considers the up-and-down nature of prevention research results […]

Report shows U.S. HIV research investment, progress; projects lasting impact from cuts

By on .

With the United States funding 70 percent of the world’s research and development of biomedical answers to HIV prevention, progress that has yielded the potential for immediate advances against the global epidemic is in danger of stalling, with lasting consequences, according to a report released at the International AIDS Society conference in Kuala Lumpur this […]

With study of injecting drug users, preventive HIV medicine demonstrates protective value to all at high risk

By on .

CDC releases updated Guidance for Pre-Exposure Prophylaxis for the Prevention of HIV Infection: PrEP for Injecting Drug Users, while questions on real-world impact remain With a five-year study in Bangkok showing that daily doses of antiretroviral medicine reduced risks of HIV infection among people who inject drugs by at least half, and more with the […]

IPrEx Findings Hold in Extension Study

By on .

Science Speaks is in Atlanta, Georgia this week and will be live-blogging from the 20th CROI — Conference on Retroviruses and Opportunistic Infections from Sunday to Wednesday, covering breaking developments from investigators on cure research, new antiretroviral agents, hepatitis, tuberculosis and treatment as prevention. ATLANTA, GA — Robert Grant from University of California at San […]

After VOICE trial, question remains: What were women telling researchers?

By on .

Science Speaks is in Atlanta, Georgia this week and will be live-blogging from the 20th CROI — Conference on Retroviruses and Opportunistic Infections from Sunday to Wednesday, covering breaking developments from investigators on cure research, new antiretroviral agents, hepatitis, tuberculosis and treatment as prevention. Perhaps at some point what the VOICE trial (Vaginal and Oral […]

Reports track current progress, pitfalls, funding and gaps of AIDS fight

By on .

On the eve of Secretary Hillary Clinton’s release of the first United States global AIDS response strategy, two reports released in recent days give a look not only of the progress so far, but of the shortfalls the new plan must address. Achieving the End, One Year and Counting, from AVAC, looks at the scientific […]

Blueprint: Use proven methods, research, determination to reach end of epidemic

By on .

Dr. Rochelle Walensky has been a member of the Cost-effectiveness of Preventing AIDS Complications (CEPAC) team since 1998. She is a member of the Office of AIDS Research Advisory Council at the National Institutes of Health and the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.  Dr. Walensky has […]

ID Week: Biomedical prevention efforts must address range of challenges

By on .

San Diego, CA — At a symposium entitled “Challenges and Opportunities in HIV Prevention today at ID Week, Jean Marrazzo offered a summation of the pre-exposure phophylaxis (PrEP) research findings and highlighted some of the nuances and unanswered questions about disparate study results. She began by defining the now widely used term “biomedical prevention” as […]

Blueprint: Dr. Myron Cohen on treatment as prevention and other essential elements of a global AIDS plan

By on .

Dr. Myron S. Cohen is the architect and principal investigator of the multinational HPTN 052 trial, which demonstrated that antiretroviral treatment prevents the sexual transmission of HIV-1. This work was recognized by Science Magazine as the “Breakthrough of the Year” in 2011. His research focuses on the transmission and prevention of transmission of HIV, and […]